Catherine Booth-Wehling

Catherine Booth-Wehling is an accomplished leader in drug metabolism and pharmacokinetics (DMPK) with extensive experience in the pharmaceutical industry. Currently serving as Executive Director and Head of Development DMPK at Bristol Myers Squibb since February 2024, Catherine has previously held significant roles at GSK, including Senior Director and Global Head of DMPK Project Specialists, where leadership of project initiatives and strategies was paramount. Additional expertise includes a position as Head of DMPK at ViiV Healthcare and a Principal Scientist role at AstraZeneca. Catherine holds a Ph.D. in Pharmaceutics from the University of North Carolina at Chapel Hill and a B.S. in Biology-Chemistry from the University of Lynchburg.